FDA amended EUA for COVID bivalent mRNA technology booster (April 18th) (Pfzier-BioNTech & Moderna for original & BA4/BA5 clades); then CDC’s ACIP advisory group met April 19th, 2023

VRBPAC (Jan 26th 2023); for this ‘simplified’ approach Dr. Wiseman below outlines the FAILURE & risk of the FDA & CDC decisions given no supporting data, omission of VAERS data on stroke signals

This article was republished from the author’s Substack.

Dr. David Weisman (excellent scholarship) is the lead scientist here:

ACIP April 19 2023: Bivalent primary series dosing with no directly supportive data and in the face of ever more resistant variants. Ischemic stroke signal in VAERS ignored. Written remarks CDC-2023-0028

SOURCE: https://www.researchgate.net/publication/370132212_ACIP_April_19_2023_Bivalent_primary_series_dosing_with_no_directly_supportive_data_and_in_the_face_of_ever_more_resistant_variants_Ischemic_stroke_signal_in_VAERS_ignored_Written_remarks_CDC-2023-0028